Gimv

Type

Private equity

Status

Active

Location

Antwerp, Belgium

Total investments

186

Average round size

21M

Portfolio companies

116

Rounds per year

4.23

Lead investments

52

Follow on index

0.37

Exits

52

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareInformation TechnologyHealth CareManufacturingMedical DeviceMedicalPharmaceuticalTherapeuticsBiopharma

Summary

Gimv is the famous VC, which was founded in 1980. The main office of represented VC is situated in the Antwerpen. The fund was located in Europe if to be more exact in Belgium.

The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Neurotech, AgroSavfe, FIRE1 Among the most successful fund investment fields, there are Therapeutics, Enterprise Software. For fund there is a match between the location of its establishment and the land of its numerous investments - Belgium. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Gimv, startups are often financed by Sofinnova Partners, Novartis Venture Fund, 3i Group. The meaningful sponsors for the fund in investment in the same round are Neomed Management, Andera Partners, VI Partners AG. In the next rounds fund is usually obtained by Sofinnova Partners, Neomed Management, HBM Healthcare Investments AG.

Besides them, we counted 31 critical employees of this fund in our database.

The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. This Gimv works on 3 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2017. Considering the real fund results, this VC is 12 percentage points more often commits exit comparing to other organizations.

Show more

Investor highlights

Industry focus
Consumer/RetailHealthcareBiotech/Life SciencesManufacturingProptech/Real Estate
Geo focus
AustriaBelgiumFranceGermanyLuxembourg Show 2 more
Check size
5M — 81M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
186
Lead investments
52
Exits
52
Rounds per year
4.23
Follow on index
0.37
Investments by industry
  • Biotechnology (74)
  • Health Care (55)
  • Medical (38)
  • Software (31)
  • Therapeutics (27)
  • Show 136 more
Investments by region
  • United States (40)
  • Belgium (40)
  • France (28)
  • Germany (19)
  • Switzerland (9)
  • Show 8 more
Peak activity year
2006
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
20
Avg. valuation at time of investment
50M
Group Appearance index
0.83
Avg. company exit year
12
Avg. multiplicator
2.46
Strategy success index
0.60

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
CoWare 02 Jun 1999 Software, Computer, Electronics Early Stage Venture 8M United States, California, San Jose
SynOx Therapeutics 19 Nov 2020 Early Stage Venture 43M Dublin, Dublin, Ireland

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.